Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D011897:Random Allocation; D013792:Thalidomide / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016898:Interferon-alpha; D061965:Matrix Metalloproteinase Inhibitors; D000068258:Bevacizumab; D013792:Thalidomide